JBR Clinical Research
Salt Lake City, Utah, 84107, United States
Location status: Recruiting
Location contact
Todd Bertoch
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07511816
The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Interested in participating?
Request Info18 year–40 year
All sexes
Interventional
Phase 2
Salt Lake City, Utah, 84107, United States
Location status: Recruiting
Todd Bertoch
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered Orally
Administered Orally
Time frame: Baseline, Up to Day 1
Time frame: Baseline, Up to Day 1
Time frame: Baseline, Up to Day 1
Time frame: Baseline, Up to Day 1
Time frame: Baseline, Up to Day 1
Time frame: Baseline, Up to Day 1
Contact information is provided by the study sponsor or research team.
Physicians interested in becoming principal investigators please contact
CONTACT
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Eli Lilly and Company
Industry
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Oral Dose of LY4515100, in Participants Experiencing Moderate-to-Severe Acute Pain Following Surgical Removal of Impacted Third Molars
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05579496
Acute Pain, Agnosia
Toronto, Ontario, Canada
View Trial DetailsNCT07698665
Acute Pain, Neurologic Manifestations
Cairo, Governorate, Egypt
View Trial DetailsNCT07562412
Acute Pain, Agnosia
Tallahassee, Florida, United States
View Trial DetailsNCT03446456
Acute Pain, Agnosia
Baltimore, Maryland, United States
View Trial Details